Could rapid brain zaps sharpen thinking in Parkinson's?

NCT ID NCT07701785

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This study tests whether a short, high-dose course of non-invasive brain stimulation called intermittent theta burst stimulation (iTBS) can safely improve mild cognitive impairment in people with Parkinson's disease. Thirty participants will receive 30 sessions of stimulation over three days, targeting a brain region linked to attention. The goal is to see if this approach is feasible, tolerable, and promising enough for larger trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
accelerated intermittent theta-burst stimulation (iTBS) delivered via transcranial magnetic stimulation (TMS) to the right superior parietal lobule
What this could lead to
If it works, this could point toward a non-invasive, short-term treatment for cognitive decline in Parkinson's disease.
What could go wrong
This is a small, early feasibility study with only 30 participants and no control group, so results may not be conclusive or generalizable. The treatment may cause temporary side effects like headache or scalp irritation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MILD COGNITIVE IMPAIRMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cognitive Dysfunction Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Medical University of South Carolina

    RECRUITING

    Charleston, South Carolina, 29425, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.